Augmenteum

Augmenteum is a privately held biotechnology company based in Menlo Park, California, specializing in the development of next-generation protein therapeutics. Founded in 2021 by David S. Wilson, an expert in protein engineering and former executive at Arcellx and Xencor, the company utilizes a proprietary platform to create "augmented" biologics. This technology is designed to enhance the pharmacological properties of proteins, such as extending half-life and improving tissue-specific targeting, to address unmet needs in oncology and immunology. Currently in the pre-clinical stage, Augmenteum is advancing a pipeline of differentiated candidates while operating largely in stealth mode.